ASPI Upcoming Business Updates Call Analysis
11/17/25
SEQH CAPITAL RESEARCH
ASP ISOTOPES BUSINESS UPDATES CALL
RESEARCH DESK
17 NOVEMBER 2025
ASP Isotopes will be giving their quarterly business updates on November 21, 2025 at 8:30am EST.
What SEQH Capital Research will be listening for specifically:
ASP Isotopes November 2025 Business Update: Advanced Focus Areas & Strategic Upside
Commercial Ramp of Core Isotopes (Silicon-28, Ytterbium-176):
Track progress on scaling production from pilot to true commercial volumes, with Silicon-28 annualized output now exceeding 80kg at 99.995%+ purity, substantially beyond earlier estimates, backed by $4M in capacity expansion investment.
With named U.S. quantum computing and semiconductor customers already secured and others in late-stage diligence, ASP cements first-mover advantage in a market favored by Western reshoring policies and supply chain sovereignty drives, potentially becoming the sole global non-Russian supplier for crucial quantum and high-performance microchip markets.
Ytterbium-176 enrichment is achieving reliable 92-99%+ levels, with validated commercial contracts for applications in both cancer therapy and next-gen photonics, positioning ASP at the intersection of deep tech and life sciences.
Carbon-12 and Carbon-14 Programs:
Expect details on resolution of feedstock risks and timelines for commercialized output, including early delivery milestones and pricing for DNA tracing, advanced materials, and nuclear medicine clients.
Carbon-12’s market pull and rapid pivot from original Carbon-14 priorities reflects a nimble R&D and commercialization culture, with addressable market expansion far beyond initial analyst models—pointing to multiple new growth verticals emerging from core tech.
Four New Laser Isotope Plants (Gadolinium-160, Zinc-68, Nickel-64, Lithium-6/7):
Focus on specific project execution metrics: construction start, capex allocation, and initial contracts, notably for Gadolinium-160, which is already under a four-year off-take agreement critical for radiopharma supply stability in oncology.
The simultaneous execution of multiple specialty isotope plants is set to transform ASP from a single-product ramp to an unmatched multi-isotope production house, driving recurring revenue, cross-sector margin stability, and entry into the PET and targeted radiotherapy markets.
Quantum Leap Energy (QLE) Spinout and HALEU Roadmap:
Scrutinize QLE’s S-1/IPO process, equity structure, HALEU facility regulatory status, and precise timelines for the Texas and South Africa plants, each critical for front-running the coming U.S. and global demand wave for advanced nuclear fuel.
ASP’s technical moat, faster-to-market laser enrichment with a smaller, modular, and capital-efficient footprint compared to large centrifuge players like Silex, may enable outsized HALEU supply share as the U.S. and international SMR sectors scale, compounding ASP’s
geopolitical premium.
